AHR agonist 10
AHR agonist 10 is a potent AHR agonist (EC50 = 2.01 nM). AHR agonist 10 can elevate the transcript levels of key AHR downstream pathway target genes, including CYP1A1 and CYP1B1. AHR agonist 10 can downregulate the expression levels of CD36, IL-18 and shows low cytotoxicity (>40 μM) to normal cells. AHR agonist 10 can suppress the expression of CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1, demonstrating that AHR agonist 10 effectively modulate inflammatory responses through AHR dependent signaling pathways. AHR agonist 10 can be used for psoriasis research.
For research use only. We do not sell to patients.
- CAS No.: 1191937-43-5
- Formula: C18H20O3
- Molecular Weight:284.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
IL-6 |
IL-8 |
In Vitro
AHR agonist 10 (Compound B19) (10 μM, 20 μM, 24 h) can effectively enhance the expression levels of CYP1A1 and CYP1B1 in the AHR knockdown HaCaT cells[1].
AHR agonist 10 (5 μM) can suppress the expression on the mRNA level of CYP1A1, CYP1B1, CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1 on the Lipopolysaccharides (HY-D1056) (LPS)-induced HaCaT cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:AHR knockdown HaCaT cell
-
Concentration:10 μM , 20 μM
-
Incubation Time:24 h
-
Result:Enhanced the expression levels of CYP1A1 and CYP1B1 on the HaCaT cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Babl/C mice (7-8 weeks old) were administered topically with Imiquimod (62.5 mg/mouse) on the hair-free back[1].
-
Dosage:1%
-
Administration:Topical application, once daily, 7 days
-
Result:Exhibited the ability to decrease the thickness of the stratum corneum and stratum spinosum of the skin , ameliorating epidermal hyperplasia.
Downregulated the expression of Ki67 and PCNA.
Mitigated psoriasis-associated epidermal hyperplasia by curbing excessive epidermal cell proliferation.
Enhanced the expression levels of ZO-1 and occludin.
Downregulated the expression levels of IL-17, IL-23, and IL-17F, effectively halting the progression of psoriasis by disrupting the responsible cytokine cascade and subsequent inflammatory response.
Effectively activated the AHR pathway, leading to enhanced expression levels of CYP1A1, CYP1B1, and HSP90.
Chemical Information
-
CAS No. 1191937-43-5
-
Molecular Weight 284.35
-
Formula C18H20O3
-
SMILES
CC(C1=C(C=C(C=C1O)/C=C/C2=CC=C(C=C2)OC)O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)